Back to Journals » Journal of Asthma and Allergy » Volume 10

Is it severe asthma or asthma with severe comorbidities?

Authors Brussino L, Solidoro P, Rolla G

Received 31 August 2017

Accepted for publication 23 October 2017

Published 29 November 2017 Volume 2017:10 Pages 303—305

DOI https://doi.org/10.2147/JAA.S150462

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Amrita Dosanjh


Luisa Brussino,1 Paolo Solidoro,2 Giovanni Rolla1

1Allergy and Clinical Immunology, University of Torino and Mauriziano Hospital, 2SC Pneumologia U, AOU Città della Salute e della Scienza, Torino, Italy

Abstract: Severe asthma is defined as asthma that requires treatment with high-dose inhaled corticosteroids (ICSs) plus a second controller and/or systemic corticosteroids to prevent it from becoming uncontrolled or that remains uncontrolled despite this therapy. This definition has limitations: 1) it does not define any biological characteristic that distinguishes severe asthma from asthma in general and 2) it relies on the clinical interpretation of asthma symptoms that are not specific. Actually, wheezing, dyspnea, cough and chest tightness may be caused by the comorbidities (such as rhinosinusitis, obesity and vocal cord dysfunction [VCD]) which are associated with asthma. In clinical practice, clinicians are often prone to diagnose uncontrolled asthma and increase doses of ICSs without considering the comorbidities, resulting in poor control of symptoms. This commentary wishes the clinicians to focus on the comorbidities of asthma, particularly in patients with severe asthma, because the correct diagnosis of these comorbidities implies specific treatments that lead to a better asthma control.

Keywords: severe asthma, chronic rhinosinusitis, obesity, vocal cord dysfunction, dupilumab

Disclosure

The authors report no conflicts of interest in this work.

References

1.

Menzella F, Galeone C, Bertolini F, et al. Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? J Asthma All. 2017;10:237–247.

2.

Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.

3.

Balfour-Lynn IM, Elborn JS. “CF asthma”: what is it and what do we do about it? Thorax. 2002;57:742–748.

4.

Bonten TN, Kasteleyn MJ, De Mutsert R, et al. Defining asthma-COPD overlap syndrome: a population-based study. Eur Respir J. 2017;49(5):1602008.

5.

Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645.

6.

Ragab S, Scadding GK, Lund VJ, et al. Treatment of chronic rhinosinusitis and its effects on asthma. Eur Respir J. 2006;28(1):68–74.

7.

Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995.

8.

Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–479.

9.

Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107(1):73–80.

10.

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 suppl):S1–S39.

11.

Scott S, Currie J, Albert P, Calverley P, Wilding JPH. Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. Chest. 2012;141(3):616–624.

12.

Van Huisstede A, Castro Cabezas M, van de Geijn GJ, et al. Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respir Med. 2013;107(9):1356–1364.

13.

van Huisstede A, Rudolphus A, Castro Cabezas M, et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax. 2015;70(7):659–667.

14.

Thomas M, McKinley RK, Freeman E, et al. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. 1. BMJ. 2001;322(7294):1098–1100.

15.

Wolfe JM, Meth BM. Vocal cord dysfunction mimicking a severe asthma attack. J Emerg Med. 1999;17(1):39–41.

16.

Balkissoon R, Kenn K. Asthma: vocal cord dysfunction (VCD) and other dysfunctional breathing disorders. Semin Respir Crit Care Med. 2012;33(6):595–605.

17.

Bucca CB, Bugiani M, Culla B, et al. Chronic cough and irritable larynx. J Allergy Clin Immunol. 2011;127:412–419.

18.

Fretzayas A, Moustaki M, Loukou I, et al. Differentiating vocal cord dysfunction from asthma. J Asthma Allergy. 2017;10:277–283.

19.

Watson MA, King CS, Holley AB, Greenburg DL, Mikita JA. Clinical and lung-function variables associated with vocal cord dysfunction. Respir Care. 2009;54(4):467–473.

20.

Thomas M, McKinley RK, Freeman E, et al. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax. 2003;58(2):110–115.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]